Burden beyond attacks: A comprehensive approach to care of Hereditary Angioedema

Funding Statement: This promotional webinar was organised and funded by BioCryst Pharmaceuticals Ireland, a Neopharmed Gentili company

Disclaimer: This webinar is intended for healthcare professionals only. Prescribing information for Orladeyo (Berotralstat) is available here. This meeting is aligned to the UK product label, please consult your local label before prescribing. Adverse Events Reporting information can be found at the bottom of this webpage.

This EMJ Allergy and Immunology webinar brings together leading experts to discuss the latest strategies for optimising hereditary angioedema management. Topics discussed include shared decision-making, treat-to-target approaches, and practical guidance on transitioning patients to modern long-term prophylaxis, including berotralstat. Featuring real-world data and a practical patient case.

1. Division of Allergy and Immunology, University of California, San Diego, USA

2. Institute of Allergology, Charité – Universitätsmedizin Berlin, Germany

3. Freie Universität Berlin, Germany

4. Humboldt-Universität zu Berlin, Germany

5. Angioedema Centre, IRCCS Policlinico San Donato, Milan, Italy

6. Department of Biomedical Sciences for Health, University of Milan, Italy

Disclosures:

Riedl has received research support from Astria, BioCryst, Biomarin, CSL Behring, Ionis, KalVista, Pharvaris, and Takeda; and speaker fees from BioCryst, CSL Behring, Grifols, Pharming, and Takeda; and  has been a consultant for Astria, BioCryst, Biomarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, Kalvista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, and Takeda.

Buttgereit is a speaker/advisor for, and/or received research funding from, Aequestive, BioCryst, CSL Behring, GSK, Hexal, KalVista, Medac, Novartis, Pharming, Pharvaris, Roche, Sanofi-Aventis, Swixx BioPharma, and Takeda.

Zanichelli has received speaker/consultancy fees from Astria, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, Otsuka, and Takeda.

UK.HAE.00307 June 2026

References:

1. Lumry WR et al. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(Suppl 1):S8-13.

2. Epland K et al. Hereditary agioedema management: individualization. J Nurse Pract. 2021;17(10):1199-203.

3. Bernstein JA. Severity of hereditary angioedema, prevalence, and diagnostic considerations. Am J Manag Care. 2018;24(14 Suppl):S292-8.

4. Lumry WR. Hereditary angioedema: the economics of treatment of an orphan disease. Front Med (Lausanne). 2018;5:22.

5. Castaldo AJ et al. Establishing a hereditary angioedema prevalence for the United States using a large administrative claims database. Ann Allergy Asthma Immunol. 2025;135(3):301-10.

6. Hide M et al. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks. Allergol Int. 2021;70(1):45-54.

7. Johnston DT. Diagnosis and management of hereditary angioedema. J Am Osteopath Assoc. 2011;111(1):28-36.

8. Agostoni A et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114 (Suppl 3):S51131.

9. Usatine RP et al. Color Atlas of Family Medicine. 2nd edn. New York: McGraw-Hill Education; 865.

10. Koruth JS et al. Gastrointest Endosc. 2005;61:907-11.

11. Bork K et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119(3):267-74.

12. Kaplan AP. Angioedema. World Allergy Organ J. 2008;1(6):103-13.

13. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-36.

14. Maurer M et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-90.

15. Bork K et al. Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. Allergy Asthma Clin Immunol. 2021;17(1):40.

16. Banerji A. The burden of illness in patients with hereditary angioedema. Ann Allergy Asthma Immunol. 2013;111(5):329-36.

17. Banerji A et al. Optimal Management of Hereditary Angioedema: Shared Decision-Making. J Asthma Allergy. 2021;14:119-25.

18. Turner D et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-83.

19. Smolen JS et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75:3-15.

20. Maurer M et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018;73(8):1575-96.

21. Zarnowski J et al. Prophylactic Treatment in hereditary angioedema is associated with reduced anxiety in patients in Leipzig, Germany. Int Arch Allergy Immunol. 2021;182(9):819-26.

22. Zanichelli A et al. Comorbidities in angioedema due to C1-Inhibitor deficiency: an Italian survey. J Allergy Clin Immunol Pract. 2024;12(4):1029-36.

23. Geba D et al. Hereditary angioedema patients would prefer newer-generation oral prophylaxis. J Drug Assess. 2021;10(1):51-6.

24. Magerl M et al. The current situation of hereditary angioedema patients in Germany: results of an online survey. Front Med (Lausanne). 2024;10:1274397.

25. Riedl M et al. Poster P008. American Academy of Allergy, Asthma and Immunology, 23-26 February, 2024.

26. Orladeyo®. Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12883/smpc. Last Accessed: 23 June 2026.

27. Zuraw B et al. Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled Phase 3 trial. J Allergy Clin Immunol. 2021;148(1):164-72.

28. Kiani-Alikhan S et al. Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the APeX-2 randomized trial. J Allergy Clin Immunol Pract. 2024;12(3):733-43.e10.

29. Maurer M et al. Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series. Allergy Asthma Clin Immunol. 2022;18(1):4.

30. Peter JG et al. Assessment of HAE prophylaxis transition from androgen therapy to berotralstat: a subset analysis of the APeX-S trial. World Allergy Organ J. 2023;16(11):100841.